复元愈肝胶囊抗大鼠肝纤维化的实验研究  

Experimental studies of Fuyuan Yugan capsule (复元愈肝胶囊) for antihepatic fibrosis in rats

作　　者：刘爱华[1] 黄骏[2] 魏江磊[1] 

机构地区：[1]上海中医药大学附属曙光医院急诊内科,上海200021 [2]湖北省十堰市人民医院,湖北十堰442000

出　　处：《中国中西医结合急救杂志》2007年第3期180-182,共3页Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care

摘　　要：目的:探讨复元愈肝胶囊抗肝纤维化的作用机制。方法:70只Wistar大鼠被随机分为正常对照组(A组,10只)、模型组(B组,12只)、秋水仙碱组(C组,12只)和复元愈肝胶囊大、中、小剂量组(D、E、F组,各12只)。除A组外,余各组均采用CCl4、高脂、高胆固醇、低蛋白等复合因素制备大鼠肝纤维化模型。同时A组和B组每日给予2 ml生理盐水;C组给予秋水仙碱0.1 mg/kg;D、E、F组分别给予复元愈肝胶囊9、4.5和2.25g/kg。于第6周末心脏取血测定血清透明质酸(HA)、层粘连蛋白(LM)、型前胶原(PC)及肝组织羟脯氨酸(HYP)含量,并观察肝组织病理改变,以判定胶原纤维增生程度。结果:B组血清HA、LM、PC及肝组织HYP含量均显著高于其他各组(P均<0.01)。与C组比较,D组血清HA、LM和PC均显著降低(P<0.05和P<0.01),且显著低于F组(P<0.05和P<0.01),而D、E、F组血清PC均显著低于C组,但3组间差异无显著性(P均>0.05)。肝组织病理观察,C、D、E和F组均可以改善肝脏病理、抑制肝纤维化形成。结论:复元愈肝胶囊具有确切的抗肝纤维化作用,且以大剂量组为优。Objective： To study the effect of Fuyuan Yugan capsule （FYYG,复元愈肝胶囊） on experimental hepatic fibrosis in rats. Methods ： Seventy Wistar rats were randomly divided into normal control group （A group, n= 10）, model group （B group, n= 12）, colchicine group （C group, n= 12） and high, middle, low dose of FYYG group （D, E, F group, each n= 12）. Hepatic fibrosis model of rat was reproduced by complex factors including carbon tetrachloride （CC1,）, high lipids, high cholesterol and low protein in all groups except A group. Two ml normal saline were given to rats in A and B group, while colchicine （0.1 mg/kg） or FYYG capsule （9, 4.5 and 2. 25 g/kg） were given to the rats in C, D, E and F group, respectively. The indexes of serum hyaluronic acid （HA）, laminin （LM）, precollagen Ⅲ （PC Ⅲ ） and the expression of hydroxyproline （HYP） in liver tissues were assayed at the end of the 6 th week. Pathological changes of liver tissues were observed to decide proliferation degree of collagenous fibers. Results： The levels of serum HA, LM, PC Ⅲ and HYP of B group were significantly higher than those of other groups （all P〈 0. 01）. Compared with C group, the levels of HA, LM and PC E of D group were significantly lower （P〈0. 05 and P〈0. 01）, and significantly lower than those of F group （P〈0.05 and P〈0.01）. The levels of serum PC Ⅲ of D, E and F group were significantly lower than those of C group. There were no significant differences in three groups （all P〈0.05）. In C, D, E and F group, the liver pathological changes were improved, and the collagenous fiber proliferation was inhibited. Conelusion： FYYG capsule shows definitely protective and therapeutic effect on experimental hepatic fibrosis especially in high dose.

关 键 词：中医药疗法 动物实验 复元愈肝胶囊 肝纤维化 

分 类 号：R285.5[医药卫生—中药学] R256.4[医药卫生—中医学]